Regado Biosciences prices IPO at $4, below revised $5 price


Regado Biosciences, which is developing break-through anticoagulant system for cardiovascular surgeries, raised $43 million by offering 10.8 million shares, 2.4 million more than anticipated, at $4, below its lowered $5 price. The company had initially filed to offer 5 million shares at a range of $14 to $16 before cutting the deal size 44% Monday morning. At its $4 offer price, Regado Biosciences commands a market cap of $82 million (63% below its initial proposed market cap) and will have approximately $52 million in cash.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

This article appears in: News Headlines , IPOs

Referenced Stocks: RGDO

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by